PMEF
KYMR icon

Point72 Middle East FZE’s Kymera Therapeutics KYMR Stock Holding History

Point72 Middle East FZE’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,629
Closed -$627K – 735
2023
Q4 		$627K Buy
+24,629
New +$440K 0.02% 752

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Middle East FZE's KYMR Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Kymera Therapeutics (KYMR) in Q1 2024, closing a stake of 24,629 shares — an estimated $627K sold.

Point72 Middle East FZE first reported a position in KYMR in Q4 2023 and held it in 1 quarter. The position peaked at $627K in Q4 2023. 164 funds tracked by Wall St. Rank hold KYMR as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Kymera Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 24,629 Kymera Therapeutics shares in Q1 2024, an estimated $627K.
  • Point72 Middle East FZE first reported a position in Kymera Therapeutics in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Kymera Therapeutics position peaked at $627K in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.